Английская Википедия:AdCLD-CoV19
Шаблон:Short description Шаблон:Use dmy dates Шаблон:Infobox drug Шаблон:COVID-19 pandemic sidebar
AdCLD-CoV19 is a COVID-19 vaccine candidate developed by Cellid Co,[1][2] a company from South Korea.[3]
A phase 1/2 trial of a single injection of AdCLD-CoV19 began in December 2020 in South Korea.[4] In September 2021, a phase 1 trial began for a single injection of another version, named AdCLD-CoV19-1.[5] Preclinical studies of a single dose in mice and non-human primates for this vaccine candidate were published in April 2022.[6] In August 2022, a phase 2 trial of 1 or 2 doses of AdCLD-CoV19-1 was registered.[7]
References
Шаблон:Vaccines Шаблон:COVID-19 pandemic Шаблон:Portal bar
Шаблон:COVID19-vaccine-stub Шаблон:Vaccine-stub
